Completed PHASE3 INTERVENTIONAL 1-arm NCT00117325

Study Of Adults And Adolescents With Vasomotor Rhinitis

A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis

Sponsor: GlaxoSmithKline

Conditions Rhinitis, Vasomotor

Interventions GW685698X

Updated 9 times since 2017 Last updated: Mar 7, 2018 Started: Jul 11, 2005 Primary completion: Feb 9, 2006 Completion: Feb 9, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Rhinitis, Vasomotor, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Mar 2018 — Jun 2018 [monthly]

Completed PHASE3
Aug 2017 — Mar 2018 [monthly]

Completed PHASE3
Jun 2017 — Aug 2017 [monthly]

Completed PHASE3
Jan 2017 — Jun 2017 [monthly]

Completed PHASE3

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Bangor, United States , Beverly Hills, United States , Bucharest, Romania , Canton, United States , Charleston, United States , Chicago, United States , Cincinnati, United States , Colorado Springs, United States , Covington, United States and 42 more locations